← Leaderboards
Leigh Ellis
Roswell Park Cancer Institute Corp
$3,518,676
Attributed
$4,900,489
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $907.2K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,900,489 · 4
By mechanism
R01$4,080,694 · 2
R21$819,795 · 2
Top collaborators
- David W Goodrich6 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Maria L Avantaggiati$6,905,214
- Steven H Bernstein$2,820,683
- Meenalakshmi Chinnam$651,060
Others in their field
Top investigators on “Androgen Receptor”
- Susan E. Hankinson · University Of Massachusetts Amherst$24,278,267
- Diane E Merry · Thomas Jefferson University$17,810,180
- Charles L Sawyers · Sloan-Kettering Inst Can Research$17,232,913
- Richard D Schulick · Johns Hopkins University$17,086,121
- Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$16,194,198
- Xiaoqi Liu · Harvard University$15,300,481
Research focus
Androgen ReceptorMalignant Neoplasm Of ProstateEpigenetic ProcessTherapeutic TargetMetastatic Prostate CancerMortalityTumorMolecularResponseNeurosecretory SystemsTherapy ResistantReceptor ExpressionRb1 GeneResistanceReceptor SignalingResistance MechanismLoss Of FunctionCancer PatientCellsMouse ModelAndrogen Deprivation TherapyPhenotypeMediatingAutomobile Driving
Grant awards (18)
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer$193,926
R01 · FY2025 · CA · contact PI
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer$260,272
R01 · FY2023 · CA · contact PI
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer$93,878
R01 · FY2023 · CA · contact PI
Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer$196,087
R21 · FY2022 · CA · contact PI
Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer$33,446
R21 · FY2022 · CA · contact PI
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer$1
R01 · FY2022 · CA · contact PI
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer$367,506
R01 · FY2021 · CA · contact PI
Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer$195,173
R21 · FY2021 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2020 · CA
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer$271,155
R01 · FY2020 · CA · contact PI
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient Prostate Cancer.$130,329
R01 · FY2020 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$490,587
R01 · FY2019 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2018 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$250,000
R01 · FY2018 · CA
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2017 · CA
Novel Mouse Models to define Genetic Drivers of Aggressive Prostate Cancer$171,281
R21 · FY2017 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2016 · CA
Novel Mouse Models to define Genetic Drivers of Aggressive Prostate Cancer$223,808
R21 · FY2016 · CA · contact PI